Senior Executive Team

David Brennan

Chief Executive Officer

David was appointed Chief Executive Officer of AstraZeneca in January 2006. From 2001 until then, David was President and Chief Executive Officer of the Company's North American subsidiary.

David began his career in 1975 at Merck, where he started as a sales representative in the US Division and later worked in sales and marketing management in the US and International divisions. He joined Astra Merck in 1992 and helped to build the joint venture into a multi-billion dollar business in the US.

He is an alumnus of Gettysburg College where he studied Business Administration.

For further information on David, see the Board of Directors at 31 December section.

Simon Lowth

Chief Financial Officer

Simon joined AstraZeneca as an Executive Director and Chief Financial Officer in November 2007. He was previously at ScottishPower where he was Finance Director. Simon left ScottishPower following completion of the sale to Iberdrola.

His move to ScottishPower followed 15 years' experience with the global management consultancy, McKinsey & Company where he advised leading multinational companies on a wide range of strategic, financial and operational issues.

Simon has an engineering degree from Cambridge University and an MBA from London Business School.

For further information on Simon, see the Board of Directors at 31 December section.

Bruno Angelici¹

Executive Vice-President, International Sales and Marketing Organisation (until 31 December)

From 2001 until 31 December 2009, Bruno was responsible for Europe, Japan, Asia Pacific, Latin America, Middle East and Africa. Before this he served as President of AstraZeneca Japan. Bruno originally joined AstraZeneca in 1989 as President of ICI Pharma France. He began his career in the food industry and then joined Baxter Healthcare where he became Managing Director for Baxter in France.

He holds an MBA from the Kellogg School of Management, Chicago, is a member of the Supervisory Board of Wolters Kluwer and is President of the Supervisory Board of Reims Management School. He was received into the Légion d'honneur in December 2009.

Bruno will be leaving AstraZeneca in 2010.

¹

Changes affecting the positions of Bruno Angelici and Tony Zook in 2010 are described in the Reserved matters and delegation of authority section.

Anders Ekblom

Executive Vice-President, Development

Before he took over responsibility for Global Drug Development, Anders was responsible for Global Clinical Development, the largest single function in R&D, operating across medicine development and life-cycle management. He joined Astra in 1993 from the Karolinska Institute and Karolinska Hospital in Stockholm, where he was a senior lecturer and Director for the Perianesthetic Unit.

Anders is President of AstraZeneca Sverige AB, and Director of Albireo Ltd. He is an Associate Professor of Physiology at the Karolinska Institute, a medical doctor qualified in anaesthesiology and intensive care, and a doctor of dental surgery. He has long been active in both basic and clinical research resulting in over 60 original publications in peer-reviewed journals and book chapters.

Christer Köhler

Interim Executive Vice-President, Discovery Research

Christer was appointed to his current role in November. He joined Astra in 1979 and held a number of R&D positions before joining Hoffmann-La Roche in Basel, Switzerland in 1992 as Global Head CNS Discovery. He returned to Astra Arcus and became Global Vice-President and Head of CNS & Pain Research in 1999 and has since been a member of the global R&D leadership team.

Christer trained at the University of Bergen Medical School where he also obtained his PhD. He conducted postdoctoral studies in Lausanne, Switzerland and the Salk Institute, San Diego US. He became adjunct Professor of Neurobiology at the University of Bergen in 1984. He has published over 150 scientific papers in different areas of neuroscience and pharmacology.

Jeff Pott

General Counsel

Jeff was appointed General Counsel from 1 January 2009 and has overall responsibility for all aspects of AstraZeneca's Legal and Intellectual Property function.

He joined AstraZeneca in 1996 and has worked in various litigation roles, where he has had responsibility for intellectual property, anti-trust and product liability litigation. Prior to joining AstraZeneca, Jeff spent five years at US legal firm Drinker Biddle and Reath, where he specialised in pharmaceutical product liability litigation and anti-trust advice and litigation.

Jeff received his bachelor's degree in Political Science from Wheaton College and his Jurus Doctor Degree from Villanova University School of Law.

David Smith

Executive Vice-President, Operations

David joined AstraZeneca in 2006 as Executive Vice-President, Operations. He leads AstraZeneca's global manufacturing and supply organisation and is also responsible for the AstraZeneca Group Safety, Health and Environment, Regulatory Compliance, Purchasing and Engineering functions. As of 27 January 2010, David has assumed overall responsibility for Corporate Information Services.

David spent his early career in pharmaceuticals, initially with the Wellcome Foundation in the UK. He subsequently spent nine years in the consumer goods sector working for Estée Lauder in New York and Timberland as Senior Vice-President Global Supply Chain. In 2003, he returned to the pharmaceutical sector and joined Novartis and was based in Switzerland.

Lynn Tetrault

Executive Vice-President, Human Resources and Corporate Affairs

Lynn was appointed Executive Vice-President, Human Resources and Corporate Affairs in 2007 having already been appointed Vice-President Corporate Affairs. She had previously been Vice-President of Human Resources for Global Drug Development and was Vice-President of Human Resources for the US subsidiary of AstraZeneca following the merger between Astra and Zeneca.

Lynn started her career in private law practice where she specialised in general corporate and healthcare law. She joined Astra USA in 1993 as Associate General Counsel in the company's legal department.

Lynn received her bachelor's degree from Princeton University and her law degree from the University of Virginia Law School.

Tony Zook¹

Chief Executive Officer, North America, President, MedImmune and Executive Vice-President, Commercial Operations

Tony has responsibility for our worldwide sales and marketing activities, including Global Marketing. He took up this newly created post on 1 January 2010 in addition to his continuing responsibilities as Executive Vice-President, North America and President of MedImmune. He joined Astra USA in 1997 as Vice-President, Marketing and Sales, having begun his pharmaceutical career at Berlex Laboratories.

Tony earned a bachelor's degree in biology from Frostburg University, and an associate's degree in chemical engineering from Pennsylvania State University. He is a member of the board for First State Innovation, the Pennsylvania Division of the American Cancer Society and is a member of the Board of Trustees for the Healthcare Leadership Council.

¹

Changes affecting the positions of Bruno Angelici and Tony Zook in 2010 are described in the Reserved matters and delegation of authority section.